SOFOSBUVIR WITH LEDIPASVIR



Hepcinat LP


Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Hepcinat LP (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Hepcinat LP

Active Ingeridents:Ledipasvir & Sofosbuvir

Company Name: Natco

Package: 28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Hepcinat LP Ledipasvir-sofosbuvir (90 mg/400 mg) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.


Store:


Hepcinat LP (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:


Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following


  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:


  • Tell your doctor or dentist that you take Hepcinat LP (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Hepcinat LP (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




Ledifos



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Ledifos (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Ledifos

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Hetero

Package: 28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Dosage and Administration:


Ledifos (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Ledifos (ledipasvir & Sofosbuvir),room temperature away from moisture and heat


Side effects:


Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:


  • Tell your doctor or dentist that you take Ledifos (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Ledifos (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Myhep LVIR



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Myhep LVIR (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Myhep LVIR

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name:Mylan

Package: 28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Dosage and Administration:


Myhep LVIR (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Myhep LVIR (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:


Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:


  • Tell your doctor or dentist that you take Myhep LVIR (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Myhep LVIR (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Ledihep



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Ledihep (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name:Ledihep

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Zydus Heptiza

Package: 28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Dosage and Administration:


Ledihep (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Ledihep (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:


Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:


  • Tell your doctor or dentist that you take Ledihep (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Ledihep (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Resof L



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Resof L(Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name:Resof L

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Zydus Heptiza

Package: 28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Resof L (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Resof L (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following


  • * Fatigue
  • * Nausea
  • * Headache
  • * Diarrhea
  • * Insomnia

Precaution:

  • Tell your doctor or dentist that you take Resof L(ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Resof L (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


SofoCure-L



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

SofoCure-L (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name:SofoCure-L

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Emcure

Package:28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


SofoCure-L (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


SofoCure-L (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • * Fatigue
  • * Nausea
  • * Headache
  • * Diarrhea
  • * Insomnia

Precaution:

  • Tell your doctor or dentist that you take SofoCure-L (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


SofoCure L (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Hepcvir L



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Hepcvir L

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Cipla

Package:28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Hepcvir L (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Hepcvir L (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:

  • Tell your doctor or dentist that you take Hepcvir L(ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Hepcvir L (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Ledviclear



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Ledviclear (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Ledviclear

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Abbott

Package:28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Ledviclear (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Ledviclear (ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:

  • Tell your doctor or dentist that you take Ledviclear (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Ledviclear (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Novisof L



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Novisof L (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name: Novisof L

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Wockhardt

Package:28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Novisof L (Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Novisof L (ledipasvir & Sofosbuvir ) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:

  • Tell your doctor or dentist that you take Novisof L (ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Novisof L (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Sofab LP



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Sofab LP (Ledipasvir and sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name:Sofab LP

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Ranbaxy

Package:28 tablets/bottle

Strength :Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Sofab LP(Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Sofab LP(ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

Adverse events associated with the use of Sofosbuvir in combination with Ribavirin may include, but are not limited to, the following

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:

  • Tell your doctor or dentist that you take Sofab LP(ledipasvir and sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Do not share needles, injection supplies, or items like toothbrushes or razors. Talk with your health care provider about ways to prevent the spread of HCV to others.

WARNING:


Sofab LP (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.


Cimivir L



Indication:


Treating chronic hepatitis C virus (HCV) infection in certain patients.

Cimivir L (Ledipasvir & Sofosbuvir) is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.



Brand name:Cimivir L

Active Ingeridents: Ledipasvir & Sofosbuvir

Company Name: Biocon

Package:28 tablets/bottle

Strength : Ledipasvir 90mg & Sofosbuvir 400mg

Mechanism of action:


Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.


Dosage and Administration:


Sofab LP(Ledipasvir-sofosbuvir (90 mg/400 mg)) is a fixed-dose combination tablet . The recommended dosage is one tablet once daily, with or without food.

Store:


Cimivir L (Ledipasvir & Sofosbuvir) room temperature away from moisture and heat


Side effects:

The following are the Common side effects.

  • fatigue
  • nausea
  • headache
  • diarrhea
  • insomnia

Precaution:

  • Tell your doctor or dentist that you take Cimivir L (Ledipasvir & Sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.
  • Tell your doctor or dentist that you take Cimivir L (Ledipasvir & Sofosbuvir) before you receive any medical or dental care, emergency care, or surgery.


WARNING:


Cimivir L (ledipasvir & Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.